Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Sees Renagel Clinical Data Driving Sales After Purchase Of GelTex

Executive Summary

Renagel sales growth will be driven by results from cardiac calcification and morbidity and mortality trials, Genzyme Chairman Henri Termeer indicated during a Sept. 11 conference call announcing Genzyme's $1 bil. acquisition of GelTex.

You may also be interested in...



Sanofi Licenses Possible Renagel/Renvela Successor From Ardelyx

The French pharma paid an undisclosed amount for rights to a preclinical phosphate transport program, one of several non-absorbable drugs that act locally within the gut. The deal comes as market-leading Renagel and Renvela face imminent generic competition.

FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies

FDA is requesting that the National Institutes of Health conduct pediatric studies on GlaxoSmithKline's bupropion agents Wellbutrin SR and Zyban

FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies

FDA is requesting that the National Institutes of Health conduct pediatric studies on GlaxoSmithKline's bupropion agents Wellbutrin SR and Zyban

Related Content

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel